Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™

References

• ICHD-3, Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211. doi:10.1177/0333102417738202
   Web of Science ®Google Scholar
• Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86–92. doi:10.1007/s11916-011-0233-z
   PubMed Web of Science ®Google Scholar
• Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain. 2019;20:41. doi:10.1186/s10194-019-0993-0
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137. doi:10.1186/s10194-020-01208-0
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14:1. doi:10.1186/1129-2377-14-1
   PubMed Web of Science ®Google Scholar
• Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2021;26. doi:10.1097/j.pain.0000000000002275
   Google Scholar
• Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–315. doi:10.1016/j.jns.2016.11.071
   PubMed Web of Science ®Google Scholar
• Yu S, Liu R, Zhao G, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–591. doi:10.1111/j.1526-4610.2011.02061.x
   PubMed Web of Science ®Google Scholar
• Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20:111. doi:10.1186/s10194-019-1062-4
   PubMed Web of Science ®Google Scholar
• Burch RC, Ailani J, Robbins MS. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2022;62:111–112. doi:10.1111/head.14245
   PubMed Web of Science ®Google Scholar
• Antonaci F, Dumitrache C, De Cillis I, Allena M. A review of current European treatment guidelines for migraine. J Headache Pain. 2010;11:13–19. doi:10.1007/s10194-009-0179-2
   PubMed Web of Science ®Google Scholar
• Chinese Medical Association Group. Guide to the prevention and treatment of migraine in China [Chinese]. Chin J Pain Med. 2016;22:721–727.
   Google Scholar
• Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24:3063–3072. doi:10.1185/03007990802457040
   PubMed Web of Science ®Google Scholar
• Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6:e010352. doi:10.1136/bmjopen-2015-010352
   PubMed Web of Science ®Google Scholar
• Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–380. doi:10.2147/DMSO.S120101
   PubMed Web of Science ®Google Scholar
• Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57:1532–1544. doi:10.1111/head.13202
   PubMed Web of Science ®Google Scholar
• Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20:68. doi:10.1186/s10194-019-1012-1
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56:S20–S28. doi:10.1212/WNL.56.suppl_1.S20
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19:107–114. doi:10.1046/j.1468-2982.1999.019002107.x
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365. doi:10.2165/00019053-199304050-00006
   PubMed Web of Science ®Google Scholar
• Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–432. doi:10.1136/jnnp.2009.192492
   PubMed Web of Science ®Google Scholar
• Yu S, Zhang Y, Yao Y, Cao H. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain. 2020;21:53. doi:10.1186/s10194-020-01117-2
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644–655. doi:10.1111/head.12055
   PubMed Web of Science ®Google Scholar
• Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ. Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. Eur J Neurol. 2018;25:811–817. doi:10.1111/ene.13621
   PubMed Web of Science ®Google Scholar
• Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53:1300–1311. doi:10.1111/head.12154
   PubMed Web of Science ®Google Scholar
• Hirata K, Ueda K, Ye W, et al. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme. BMC Neurol. 2020;20:274. doi:10.1186/s12883-020-01848-4
   PubMed Web of Science ®Google Scholar
• Lombard L, Ye W, Nichols R, Jackson J, Cotton S, Joshi S. A real-world analysis of patient characteristics, treatment patterns, and level of impairment in patients with migraine who are insufficient responders vs responders to acute treatment. Headache. 2020;60:1325–1339. doi:10.1111/head.13835
   Web of Science ®Google Scholar
• Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2016;56:1635–1648. doi:10.1111/head.12941
   PubMed Web of Science ®Google Scholar
• Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688–695. doi:10.1212/WNL.0000000000001256
   PubMed Web of Science ®Google Scholar
• Migraine: developing drugs for acute treatment guidance for industry; 2018. Available from: https://www.fda.gov/media/89829/download. Accessed 25, June 2021.
   Google Scholar
• Lipton RB, Hamelsky SW, Kolodner KB, Steiner TF, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2001;55:629–635. doi:10.1212/WNL.55.5.629
   Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2010;31:301–315. doi:10.1177/0333102410381145
   PubMed Web of Science ®Google Scholar
• Doane MJ, Gupta S, Fang J, Laflamme AK, Vo P. The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther. 2020;9:535–549. doi:10.1007/s40120-020-00196-2
   Web of Science ®Google Scholar
• Torres-Ferrús M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37:104–113. doi:10.1177/0333102416636055
   PubMed Web of Science ®Google Scholar
• Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22:29. doi:10.1186/s10194-021-01243-5
   PubMed Web of Science ®Google Scholar